27T51 + cemiplimab

27T51 + cemiplimab is a combination drug consisting of an unspecified agent referred to as 27T51 and cemiplimab, a monoclonal antibody targeting the programmed death receptor-1 (PD-1). Cemiplimab acts as an immune checkpoint inhibitor by blocking the PD-1/PD-L1 pathway, thereby enhancing T-cell–mediated immune responses against tumors. Cemiplimab is developed primarily for oncology indications, including cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer. The nature, mechanism of action, or other properties of 27T51 are not defined in any available authoritative sources, and it does not correspond to a recognized pharmaceutical, investigational agent, or known code name in the literature or regulatory documentation[1][2][5][6].

Other names

cemiplimab-rwlc